Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. (NYSE: ALUR) is a medical device company focused on metabolically healthy weight loss through its Allurion Program and Allurion Smart Capsule. This news page aggregates company press releases and third-party coverage so readers can review how Allurion communicates progress on its weight-loss platform, clinical studies, regulatory milestones, and capital markets activity over time.
Company announcements frequently highlight developments related to the Allurion Smart Capsule, described as the world’s first and only swallowable, Procedureless™ gastric balloon for weight loss, and the Allurion Virtual Care Suite, which includes the Allurion Mobile App, Allurion Insights with the Iris AI Platform, and the Allurion Connected Scale. News items also cover the company’s strategic focus on metabolically healthy weight loss, including combination approaches with low-dose GLP-1 therapies and efforts to maintain or increase lean body mass in patients with overweight and obesity.
Investors and observers can use this page to follow updates on clinical evidence, such as peer-reviewed publications and case series involving the Smart Capsule, lifestyle interventions, and GLP-1 combination therapy. Allurion’s releases describe multicenter studies, case-controlled analyses, and outcomes related to weight reduction, fat mass loss, visceral fat loss, and body composition.
In addition, Allurion’s news flow includes regulatory and financial milestones, including progress in the FDA PMA process for the Allurion Smart Capsule, FDA inspections, Day-100 meetings, private placements of equity and warrants, and transactions to exchange outstanding debt for convertible preferred equity. Readers interested in ALUR news can consult this feed to see how the company reports on its operating strategy, financial results, and key risk disclosures over time.
Allurion Technologies (NYSE: ALUR) has announced plans to initiate a clinical study combining the Allurion Balloon with GLP-1 agonists to treat obesity. The study aims to demonstrate improved long-term tolerability and adherence to GLP-1 therapy using lower doses.
Current data shows that 30% of patients discontinue GLP-1 therapy within the first month, and 58% stop before achieving meaningful health benefits due to side effects, dose escalation requirements, and cost. Previous research, published in Obesity Surgery, demonstrated enhanced weight loss and co-morbidity resolution at four months when combining the Allurion Balloon with oral semaglutide compared to balloon therapy alone.
Allurion Technologies (NYSE: ALUR) has received clearance from ANSM, the French regulatory authority, to resume sales of the Allurion Balloon in France, historically their top-performing market representing approximately 15% of revenue. The company is also exploring clinical trials in French clinics to study the combination of the Allurion Balloon with GLP-1s, aiming to address muscle mass loss during obesity treatment.
In France, approximately 47% of the population has excess weight, with 17% classified as obese. While GLP-1 therapies have shown to reduce lean mass by about 40% of total weight lost, previous studies of the Allurion Balloon combined with Virtual Care Suite demonstrated that patients can lose weight while maintaining or increasing muscle mass. In one study of 571 patients, subjects gained 5.6% in lean body mass while losing 14% of total body weight over four months. Another study with 167 patients showed a 15.7% weight reduction with no muscle mass loss.
Allurion Technologies (NYSE: ALUR) has announced a registered direct offering of 1,240,000 shares of common stock priced at $6.00 per share, aiming to raise approximately $7.4 million in gross proceeds. The offering is priced at-the-market under NYSE rules.
In a concurrent private placement, the company will issue warrants to purchase up to 1,240,000 additional shares at an exercise price of $6.00 per share. These warrants will become exercisable immediately following stockholder approval and will expire five years after such approval. The company also agreed to reprice its outstanding warrants from July 2024 to $6.00 per share for existing warrant holders participating in this offering.
Roth Capital Partners is serving as the exclusive placement agent. The offering is expected to close around January 27, 2025. The proceeds will be used for working capital and general corporate purposes.
Allurion Technologies (NYSE: ALUR) has announced plans to start a clinical study combining its Allurion Program with GLP-1 agonists to optimize muscle mass during weight loss treatment. The initiative addresses a significant concern with GLP-1 therapy, which has shown approximately 40% reduction in lean mass as a proportion of total weight lost.
Previous studies of the Allurion Balloon combined with their Virtual Care Suite have demonstrated promising results: In a study of 571 patients, participants gained 5.6% in lean body mass while losing 14% of total body weight over four months. Another study with 167 patients showed a 15.7% weight reduction with no muscle mass loss.
The company aims to prove that combining their balloon technology with GLP-1 therapy could become the gold standard for obesity care by enabling significant weight loss while improving muscle mass and body composition.
Allurion Technologies (NYSE: ALUR) announced the issuance of a new U.S. patent for their next-generation weight loss device. The U.S. Patent No. 12,209,677, titled “Binary Fluid Control Valve System,” was issued on January 15, 2025. This patent covers enhanced claims for Allurion's proprietary Balloon technology, specifically focusing on the precision of its valve system. The patent provides protection through July 2039. This addition brings Allurion's patent portfolio to 20 U.S. patents and 59 global patents.
The Allurion Program combines the Allurion Gastric Balloon, a swallowable and procedure-less gastric balloon, with the Allurion Virtual Care Suite, including a mobile app, connected scale, and Allurion Insights for healthcare providers. Patients using the Allurion Program typically lose 10-15% of their total body weight and can increase muscle mass in some cases.
Shantanu Gaur, Allurion’s Founder and CEO, emphasized that the new patent strengthens their global patent portfolio, reflecting the innovation and effectiveness of their weight loss solutions.
Allurion Technologies (NYSE: ALUR) has announced a private placement agreement with RTW Investments for 841,751 shares at $2.97 per share, expected to generate $2.5 million in gross proceeds. The agreement includes an option for up to $10 million in additional funding tranches and is set to close around January 15, 2025.
The company also released preliminary Q4 2024 results, with expected revenue of approximately $5.6 million for the quarter and $32 million for the full year 2024, meeting previous guidance. Procedure volume growth for the year, excluding France, is estimated at 4%, exceeding earlier projections.
The funding is expected to extend the company's runway through early 2026, supporting their 2025 plans including scaling commercial strategy, advancing FDA approval process for the Allurion Balloon, working toward profitable operations in 2026, expanding digital business lines, and resuming French market operations.
Allurion Technologies (NYSE: ALUR) announced positive topline results from its AUDACITY trial, evaluating the safety and efficacy of the Allurion Balloon. This pivotal FDA trial is the first to report primary outcomes beyond 9 months for an intragastric balloon for weight loss. The trial included 550 subjects randomized 1:1 to either two cycles of the Allurion Balloon or a control group receiving moderate intensity lifestyle therapy.
At 48 weeks, over 50% of Allurion Balloon subjects lost more than 5% of their total body weight (58%; p-value = 0.0089). The Allurion Balloon group exhibited a 3.77% mean difference in total body weight loss compared to the control group, with a 2.69% superiority margin, which was under the pre-specified 3% margin (p-value=0.1616). At 40 weeks, the mean difference was 4.22%, exceeding the 3% margin.
The trial reported a low 3.1% rate of serious adverse events, the lowest for a liquid-filled intragastric balloon in an FDA trial. The fourth and final module of the Pre-Market Approval application is planned for 2025.
Allurion Technologies (NYSE: ALUR) announced a 1-for-25 reverse stock split effective January 3, 2025. The split will reduce outstanding shares from approximately 67.8 million to 2.7 million, with no fractional shares issued. Trading on NYSE will begin on a split-adjusted basis on January 3, 2025.
The decision follows NYSE's notification on August 12, 2024, regarding non-compliance with the minimum $1.00 per share requirement. Proportional adjustments will be made to equity incentive plans, convertible notes, and warrants. Post-split, public warrants (ALUR WS) will be exercisable for 0.056818 shares at $202.50 per share.
Allurion Technologies (NYSE: ALUR) announced that the NYSE has accepted its plan to regain compliance with the exchange's Minimum Market Capitalization Standard. The company, focused on ending obesity, has until March 1, 2026 to meet the listing requirements outlined in Section 802.01B of the NYSE's Listed Company Manual. Dr. Shantanu Gaur, Founder and CEO, expressed satisfaction with this development and emphasized their commitment to increasing shareholder value.
Allurion Technologies (NYSE: ALUR) has launched AllurionMeds, combining compounded GLP-1 medications with an AI-powered platform featuring Coach Iris for weight management. The program includes virtual dietician access and a smart scale measuring weight, muscle, and bone mass. The initiative addresses key GLP-1 challenges: medication adherence, muscle mass loss, and high costs. The program utilizes FDA-registered pharmacies for drug sourcing and expands Allurion's presence to all 50 US states. This launch targets a projected $100 billion GLP-1 market expected to reach 30 million users by 2030.
FAQ
What is the current stock price of ALLURION TECHNOLOGIES (ALUR)?
What is the market cap of ALLURION TECHNOLOGIES (ALUR)?
